Join the SmallCapReview mailing list.

MYGN Myriad Genetics: A  personalized medicine company, that focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. MYGN has a collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. More.   
AUPH Aurinia Pharmaceuticals: A late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.  More.
ICPT Intercept Pharmaceuticals: A biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry.  OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC.  More.     

Here's Where Smaller Stocks Could Go In The Next Few Months

Can Small Caps Resume Their Rocket Ride?

Small Cap Dividends

6 Small Cap Trends To Watch

Small Caps And Financials Pop As Bullish Jobs Give Jolt

Volume Leaders
52 Week Highs/Lows
Small-Cap Index
Check Futures Here
Level II Quotes
Stock Screener
Performance by Industry
After Hours Market
World Markets


Visit Our Resources Page

Past Articles Worth Reading











 Where Small Cap Stocks Thrive Since 1999                                           

5 Small Caps Breaking Out To New Highs

Investing Or Betting...

A Small Cap Pause That Refreshes...

Aurinia Completes Licensing Deal With Merck Animal Health...(AUPH)

The Small Cap Investing Handbook...

U.S. Defense Stocks Easily Outperform Broader Market...

Why We Invest...

5 Small Caps For The Long Term...

Review Of U.S. Small Cap Stocks 2017...

9 Small Cap Stocks With Wide Moats...

Small Cap Stocks To Watch...

Aurinia Pharmaceuticals (AUPH)



"Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe."

More on AUPH here...

Myriad Genetics (MYGN)


"Myriad has the deepest diagnostic pipeline across the disease spectrum."

More on MYGN here...

Intercept Pharmaceuticals (ICPT)


"A Biopharmaceutical Company Focused On The Development And Commercialization Of Novel Therapeutics To Treat Chronic Liver Diseases."

More On ICPT here...

Follow Us On


Why Small Caps And Quality Can Be A Powerful Combination

The Message In Small Cap Performance

Dollar Cost Averaging

Aurinia Announces Development Plans for Voclosporin in Europe and Japan...(AUPH)

10 Small Cap Stocks That Could Double In The Next Three Months

Why Now Is A Good Time To Own Small Cap Banks

Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017)...AUPH

Rate Hike Creates New Opportunity In Small Caps

Myriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting...(MYGN)

Where Small Caps Are Less Risky

Cup With Handle Chart Pattern

Small Cap Biotechs Gain Steam As Cutting Regulations Are On The Table

Return On Equity

Oil, Small Banks, Move Small Caps

Your Mutual Find Manager Has Failed You For The Past 15 Years

2017: Year Of The Small Cap Stock

7 Small Caps With Big Dividends

5 Beaten Down Value Stocks

Where Small Caps Are Working

Define Small Cap Stock

Small Cap Tick Pilot Program Disappointing

Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common...(AUPH)

Best Small Caps By Share Price Growth

Aurinia Announces Acceptance of Voclosporin Late-Breaking Presentation at the National Kidney Foundation 2017 Spring Clinical Meetings...(AUPH)

Small Cap Defense

Subscribers to our Free newsletter will receive stock reports and news alerts for small-cap stocks via email. You can sign-up here.

"A Primer In Small Cap Investing"® is a leading destination for small-cap picks and news. The Purpose of is to profile and bring awareness to companies with a market cap of less than $1 billion, these small-cap stocks will primarily trade on the Nasdaq Small-Cap market. We also issue daily small cap stocks to watch via various newswires. We will strive to bring you the undiscovered, the undervalued, and the oversold. does not give "buy" recommendations, price targets nor suggest entry and exit points.

"A Look at Small Cap Stocks that may no longer be Small Caps"




© 1999-2017 Any questions or comments regarding this site should be directed to